Analyzing MusclePharm (OTCMKTS:MSLP) & Rani Therapeutics (NASDAQ:RANI)
Analyzing MusclePharm (OTCMKTS:MSLP) & Rani Therapeutics (NASDAQ:RANI)
MusclePharm (OTCMKTS:MSLP – Get Rating) and Rani Therapeutics (NASDAQ:RANI – Get Rating) are both small-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.
穆斯克莱帕姆(场外交易代码：MSLP-GET评级)和拉尼治疗公司(纳斯达克：RANI-GET评级)都是小型消费品公司，但哪一家更好？我们将根据这两家公司的收益、股息、估值、机构所有权、盈利能力、风险和分析师的建议来比较它们的实力。
Institutional and Insider Ownership
机构和内部人持股
15.5% of MusclePharm shares are held by institutional investors. Comparatively, 6.4% of Rani Therapeutics shares are held by institutional investors. 60.7% of MusclePharm shares are held by company insiders. Comparatively, 52.3% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
该公司15.5%的股份由机构投资者持有。相比之下，Rani治疗公司6.4%的股份由机构投资者持有。MusclePharm 60.7%的股份由公司内部人士持有。相比之下，Rani治疗公司52.3%的股份由公司内部人士持有。强大的机构持股表明，大型基金管理公司、对冲基金和捐赠基金相信，一家公司有望实现长期增长。
Earnings and Valuation
收益和估值
This table compares MusclePharm and Rani Therapeutics' revenue, earnings per share and valuation.
下表比较了MusclePharm和Rani治疗公司的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MusclePharm | $50.04 million | 0.00 | -$12.87 million | ($0.58) | 0.00 |
| Rani Therapeutics | $2.72 million | 107.98 | -$8.33 million | ($1.20) | -4.96 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 穆斯克尔帕姆 | 5,004万美元 | 0.00 | -1287万美元 | ($0.58) | 0.00 |
| 拉尼治疗公司 | 272万美元 | 107.98 | -833万元 | ($1.20) | -4.96 |
Rani Therapeutics has lower revenue, but higher earnings than MusclePharm. Rani Therapeutics is trading at a lower price-to-earnings ratio than MusclePharm, indicating that it is currently the more affordable of the two stocks.
Rani治疗公司的收入较低，但比MusclePharm的收入高。Rani Treateutics的市盈率低于MusclePharm，这表明它目前是两只股票中更负担得起的一只。
Analyst Ratings
分析师评级
This is a summary of recent recommendations and price targets for MusclePharm and Rani Therapeutics, as reported by MarketBeat.com.
据MarketBeat.com报道，这是MusclePharm和Rani治疗公司最近的建议和价格目标的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MusclePharm | 0 | 0 | 0 | 0 | N/A |
| Rani Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 穆斯克尔帕姆 | 0 | 0 | 0 | 0 | 不适用 |
| 拉尼治疗公司 | 0 | 0 | 3 | 0 | 3.00 |
Rani Therapeutics has a consensus target price of $22.00, suggesting a potential upside of 269.75%. Given Rani Therapeutics' higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than MusclePharm.
Rani Treateutics的共识目标价为2200美元，暗示潜在上涨269.75%。考虑到Rani治疗公司更有可能上行，分析师们显然认为Rani治疗公司比MusclePharm更有利。
Profitability
盈利能力
This table compares MusclePharm and Rani Therapeutics' net margins, return on equity and return on assets.
此表比较了MusclePharm和Rani治疗公司的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| MusclePharm | -38.51% | N/A | -169.56% |
| Rani Therapeutics | N/A | -25.86% | -23.88% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 穆斯克尔帕姆 | -38.51% | 不适用 | -169.56% |
| 拉尼治疗公司 | 不适用 | -25.86% | -23.88% |
Risk and Volatility
风险和波动性
MusclePharm has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.
MusclePharm的贝塔系数为-0.07，这表明其股价的波动性比标准普尔500指数低107%。相比之下，Rani Treateutics的贝塔系数为0.52，这表明其股价的波动性比标准普尔500指数低48%。
Summary
摘要
Rani Therapeutics beats MusclePharm on 7 of the 13 factors compared between the two stocks.
Rani治疗公司在两只股票之间进行比较的13个因素中有7个超过了MusclePharm。
About MusclePharm
关于MusclePharm
(Get Rating)
(获取评级)
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
公司在美国和国际上开发、制造、营销和分销运动营养品和营养补充剂。该公司提供一系列高性能粉末、胶囊、片剂、凝胶和随时可用的零食。该公司的MusclePharm品牌产品组合包括战斗蛋白粉和战斗挤压蛋白棒；以及支链氨基酸、肌酸、谷氨酰胺、肉碱、共轭亚油酸、鱼油、多种维生素和其他产品等基本补充剂。该公司还提供FitMisse品牌的运动营养产品，这些产品主要是为女性身体制定的，以支持女性在体重管理、瘦肌肉质量、身体成分以及一般健康和健康方面的需求；以及FitMisse Energy和FitMisse Energy品牌的功能能量饮料。它向各种运动员和健身爱好者销售其产品。该公司成立于2006年，总部设在内华达州拉斯维加斯。
About Rani Therapeutics
关于Rani治疗公司
(Get Rating)
(获取评级)
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Rani治疗控股公司是一家临床阶段的生物治疗公司，开发口服生物制剂。该公司开发了RaniPill胶囊，这是一个旨在用口服剂量取代皮下或静脉注射生物制品的平台。其产品线包括用于治疗神经内分泌肿瘤和肢端肥大症的奥曲肽RT-101，用于治疗神经内分泌肿瘤和肢端肥大症的第一阶段临床试验；用于治疗牛皮癣关节炎的抗肿瘤坏死因子-α抗体RT-105；用于治疗骨质疏松症的甲状旁腺激素RT-102；用于治疗生长激素缺乏的人类生长激素RT-109；用于治疗甲状旁腺功能减退症的甲状旁腺激素RT-110；以及用于治疗2型糖尿病的基础胰岛素RT-106。该公司成立于2012年，总部位于加利福尼亚州圣何塞。
Receive News & Ratings for MusclePharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MusclePharm and related companies with MarketBeat.com's FREE daily email newsletter.
接受MusclePharm日报的新闻和评级-在下面输入您的电子邮件地址，即可通过MarketBeat.com的免费每日电子邮件时事通讯收到对MusclePharm和相关公司的最新新闻和分析师评级的每日简要摘要。